This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

The Effectiveness of Intravitreal Avastin Injection for CRVO

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified August 2012 by Ziv Hospital.
Recruitment status was:  Recruiting
Information provided by (Responsible Party):
Ziv Hospital Identifier:
First received: August 29, 2012
Last updated: NA
Last verified: August 2012
History: No changes posted
to determine the effectivness of intravitreal avastin injection on visual acuity on people that suffer from central retinal vein occlusion

Central Retinal Vein Occlusion

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Retrospective
Official Title: The Effectiveness of Intravitreal Avastin Injection for CRVO

Further study details as provided by Ziv Hospital:

Estimated Enrollment: 68
Study Start Date: January 2006

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
patients who suffer from CRVO and were injected by bevazicumab intravitrealy

Inclusion Criteria:

  • patients above 18 years old
  • suffer from CRVO
  • maximal visual acuity 6/15

Exclusion Criteria:

  • VA of LP
  • retinal disease other than CRVO
  • incomplete medical record
  • follow up less than 6 months
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01678248

Contact: Joseph pikkel, M.D 972508434206
Contact: Otzem Chassid, M.D 972506266059

Ziv Medical Center Recruiting
Safed, Israel, 13100
Contact: Otzem Chassid, M.D   
Principal Investigator: Joseph Pikkel, M.D         
Sponsors and Collaborators
Ziv Hospital
  More Information

Responsible Party: Ziv Hospital Identifier: NCT01678248     History of Changes
Other Study ID Numbers: 0048-12-ZIV
Study First Received: August 29, 2012
Last Updated: August 29, 2012

Additional relevant MeSH terms:
Retinal Vein Occlusion
Retinal Diseases
Eye Diseases
Venous Thrombosis
Embolism and Thrombosis
Vascular Diseases
Cardiovascular Diseases
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Antineoplastic Agents processed this record on August 18, 2017